Skip to main content

Advertisement

Table 3 Detection limits of the Discovery assay

From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Cytokine Samples within standard curvea Cytokine Samples within standard curvea Cytokine Samples within standard curvea
BCA-1 47/47 (100%) IL-6 43/47 (91%) MCP-3 20/47 (43%)
CTACK 47/47 (100%) IL-7 26/47 (55%) MCP-4 46/47 (98%)
EGF 38/47 (81%) IL-8 39/47 (83%) MDC 47/47 (100%)
ENA-78 47/47 (100%) IL-9 47/47 (100%) MIP-1α 34/47 (72%)
Eotaxin-1 47/47 (100%) IL-10 42/47 (89%) MIP-1β 44/47 (94%)
Eotaxin-2 45/47 (96%) IL-12P40 27/47 (57%) MIP-1d 47/47 (100%)
Eotaxin-3 47/47 (100%) IL-12P70 41/47 (87%) PDGF-AA 47/47 (100%)
FGF-2 47/47 (100%) IL-13 22/47 (47%) PDGF-BB 46/47 (98%)
Flt-3 Ligand 20/47 (43%) IL-15 46/47 (98%) RANTES 37/47 (79%)
Fractalkine 42/47 (89%) IL-16 47/47 (100%) sCD40L 47/47 (100%)
G-CSF 40/47 (85%) IL-17A 39/47 (83%) SCF 20/47 (43%)
GM-CSF 40/47 (85%) IL-18 43/47 (91%) SDF-1 46/47 (98%)
GRO pan 45/47 (96%) IL-20 45/47 (96%) TARC 47/47 (100%)
IFNα2 42/47 (89%) IL-21 22/47 (47%) TGF-a 36/47 (77%)
IFNγ 36/47 (77%) IL-23 45/47 (96%) TNFα 47/47 (100%)
IL-1α 46/47 (98%) IL-28A 46/47 (98%) TNFβ 22/47 (47%)
IL-1B 35/47 (74%) IL-33 29/47 (62%) TPO 39/47 (83%)
IL-1RA 40/47 (85%) IP-10 47/47 (100%) TRAIL 47/47 (100%)
IL-2 28/47 (60%) I-309 47/47 (100%) TSLP 42/47 (89%)
IL-3 47/47 (100%) LIF 33/47 (70%) VEGF-A 32/47 (68%)
IL-4 19/47 (40%) MCP-1 47/47 (100%) 6CKINE 47/47 (100%)
IL-5 36/47 (77%) MCP-2 47/47 (100%)   
  1. aPercentage of the 47 plasma samples with target protein fluorescence intensity values within the protein standard curve. Absolute cytokine concentration for 15/65 cytokines (shown in bold) could not be calculated in more than 75% of plasma samples because fluorescence intensity values were below the standard curve